HSP90AA1

Overview

HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1; Wikidata: Q18027367) is a human gene encoding the cytosolic, stress-inducible isoform of the 90 kDa heat shock protein (HSP90α), a highly conserved ATP-dependent molecular chaperone. As a member of the HSP90 family, HSP90AA1 plays a central role in the folding, stabilization, maturation, and degradation of a broad repertoire of client proteins — including kinases, transcription factors, and steroid hormone receptors — thereby functioning as a master regulator of cellular proteostasis. Its expression is markedly upregulated under conditions of cellular stress, including elevated temperature, hypoxia, and oxidative stress, which has positioned it as a sentinel of the cellular stress response. HSP90AA1 is also a critical scaffold within signal transduction networks, mediating the activity of oncoproteins and pro-survival pathways such as PI3K/Akt/mTOR and STAT3/HIF-1α, among others.

The broad involvement of HSP90AA1 in oncogenic signaling, inflammation, and metabolic disease has made it a high-priority therapeutic target across numerous disease contexts. Its overexpression in malignant tissues relative to normal counterparts enables tumor-selective targeting strategies. Beyond oncology, accumulating evidence implicates HSP90AA1 in cardiovascular diseases, neurodegeneration, fibrosis, and diabetic complications — underscoring the gene's pleiotropic biological significance and therapeutic versatility.

Recent Publications Focus

Below is a summary of the newest research publications targeting HSP90AA1 (sorted by publication date).

Recent studies have continued to place HSP90AA1 at the center of multi-omics, network pharmacology, and experimental validation workflows across diverse disease settings. In type 2 diabetic sarcopenia, HSP90AA1 emerged as one of seven oxidative stress-related hub genes identified through integrated single-cell and bulk RNA sequencing with machine learning, alongside TNFRSF1B, PSMA2, UBE2D1, UBE2N, RAD23A, and DNAJB1. The analysis linked these genes to neuromuscular junction and myofiber biology, with enrichment in proteasome, TNF signaling, and ubiquitin-mediated proteolysis pathways, suggesting a role for HSP90AA1 in the protein degradation processes associated with muscle atrophy. In lung adenocarcinoma, HSP90AA1 was also identified as a hub toxicological target in a PFAS-focused multi-omics study, where it appeared with EGFR, Akt1, ALB, SRC, and ESR1 in networks enriched for PPAR signaling, chemical carcinogenesis-receptor pathways, and thyroid hormone signaling.

Several publications examined HSP90AA1 in cancer-related signaling and natural product pharmacology. In oral squamous cell carcinoma, HSP90AA1 was among the upregulated hub genes associated with poorer survival, and integrative docking, molecular dynamics, and cell-based experiments supported hippeastrine as a compound that suppresses the HSP90/PI3K/Akt/mTOR axis. In hepatocellular carcinoma, HSP90AA1 was one of five core hub genes overexpressed in tumors and was downregulated after quercetin treatment in HepG2 cells, consistent with computational predictions and enrichment in cell cycle, p53, and FoxO signaling pathways. In another nutraceutical-focused cancer study, HSP90AA1 appeared among the key hub nodes in a Vernolac network pharmacology analysis, together with Akt1, BCL2, CASP3, CTNNB1, EGFR, ESR1, GAPDH, HSP90AB1, IL6, JUN, SRC, STAT3, and TNF, supporting a multi-target anticancer framework. A separate study of Yinxingye tablets also identified HSP90AA1 as a hub target in antioxidant stress-related networks, alongside SRC, CASP3, MAPK8, MMP9, IGF1, RAF1, and PPARG.

Outside oncology, HSP90AA1 was implicated in neuronal injury, fibrosis, and metabolic disease. In elderly postoperative cognitive dysfunction, Sevoflurane was reported to bind HSP90AA1 stably in docking analyses and to increase HSP90AA1 expression in HT22 hippocampal neurons; knockdown of HSP90AA1 reversed Sevoflurane-induced reductions in viability and increases in oxidative stress, mitophagy markers, and apoptosis, indicating that HSP90AA1 contributes to Sevoflurane-mediated neuronal injury. In diabetic nephropathy, network pharmacology and docking identified HSP90AA1 as a putative target of trehalose, and functional validation showed that recombinant HSP90AA1 reversed trehalose’s inhibitory effect on profibrotic gene expression in TGF-β1-challenged mesangial cells, while HSP90AA1 knockdown enhanced it. In pulmonary fibrosis, HSP90AA1 was proposed as part of a STAT3/HSP90AA1 and HIF-1α crosstalk axis underlying the anti-EMT effects of diammonium glycyrrhizinate and vitamin D3.

Additional work reinforced HSP90AA1 as a broadly relevant hub in disease networks and therapeutic targeting. In intrahepatic cholangiocarcinoma, HSP90 inhibition was reported to synergize with anti-PD1 in inflammatory tumors, highlighting HSP90 pathway dependence in a specific molecular subgroup. In a study of HSP90-dependent bioorthogonal PROTAC prodrug design, HSP90AA1 was not the direct target but served as the enabling tumor-selective component for enhanced degradation of BRD4 and Bcl-xL, underscoring the translational value of HSP90 biology in selective protein degradation strategies. Across these publications, HSP90AA1 repeatedly appeared as a central node linking oxidative stress, inflammation, proteostasis, mitophagy, and oncogenic signaling, and it was frequently paired with computational docking, network analysis, and targeted knockdown or rescue experiments to support mechanistic claims.

Background PMIDs

• [PMID 41720180]

Target PMIDs

• [PMID 41423159]
• [PMID 41839264]
• [PMID 41846052]
• [PMID 41916296]
• [PMID 42104588]
• [PMID 42145839]
• [PMID 42149022]
• [PMID 42216572]
• [PMID 42334505]
• [PMID 42370964]
• [PMID 42384725]
• [PMID 42412755]

Conclusion PMIDs

• [PMID 42370964]